Key result
Review highlights balance of mortality benefits versus bleeding risks for antithrombotic therapy in ACS with CKD.
Why the study?
Patients with CKD presenting with ACS have higher mortality and bleeding risk, yet most randomized trials of antiplatelet and antithrombotic drugs exclude them despite guidelines relying on those trials.
What are the safety and efficacy of antiplatelet and antithrombotic therapies in patients with chronic kidney disease presenting with acute coronary syndrome?
What are the safety and efficacy of antiplatelet and antithrombotic therapies in patients with chronic kidney disease presenting with acute coronary syndrome?
This review summarizes the safety and efficacy of antiplatelet and antithrombotic therapies in patients with acute coronary syndrome and chronic kidney disease, a high-risk population frequently excluded from randomized trials.
CKD patients underrepresented in ACS trials; leaves open optimal antithrombotic strategies for this high-bleeding-risk group.
Chronic kidney disease (CKD) is prevalent and affects an ever-increasing proportion of patients presenting with acute coronary syndrome (ACS). Patients with CKD have a higher risk of ACS and significantly higher mortality, and are also predisposed to increased bleeding complications. Antiplatelet and antithrombotic drugs form the bedrock of management of patients with ACS. Most randomized trials of these drugs exclude patients with CKD, and current guidelines for management of these patients are largely based on these trials. We aim to review the safety and efficacy of these drugs in patients with CKD presenting with ACS.
No takes yet. Share an insight, caveat, or question.
Basra et al. (2011) conducted a review in Acute coronary syndrome with chronic kidney disease. Antiplatelet and antithrombotic therapy was evaluated on Safety and efficacy (mortality and bleeding complications). Antiplatelet and antithrombotic therapies are reviewed for safety and efficacy in acute coronary syndrome patients with chronic kidney disease, who face higher mortality and bleeding risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: